The COVID-19 pandemic has abruptly affected drug manufacturing in the United States. This now includes the production of Tepezza, the only FDA-approved medical therapy for thyroid eye disease.
The temporary suspension has disrupted its supply chain, delaying the initiation of treatment of many patients in whom it is medically indicated. In addition, ongoing therapy with Tepezza (teprotumumab-trbw) has been interrupted. Horizon Therapeutics, the manufacturer of Tepezza, has publicly reported that this disruption in drug availability may extend through the first quarter of 2021. During this
Uncategorized